BARI 2D STUDY

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。BARI 2D试验是美国国立卫生研究院（nih）赞助的、研究者发起的、多中心临床试验，其目的是确定2型糖尿病和稳定的、有记录的冠状动脉疾病患者，采用(1)初始冠状动脉血运重建术（PTCA或CABG）联合强化药物治疗与单独强化药物治疗相比，5年死亡率是否更低；(2)胰岛素增敏方案与胰岛素提供方案实现的血糖控制（均达到HbA1c <7.0%的目标水平）。UAB是参与该试验的约50个临床中心之一，约2400名患者随访5-7年。这项研究目前正处于招募阶段，尚未有任何结果或出版物。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The BARI 2D trial is an NIH-sponsored, investigator-initiated, multicenter clinical trial whose objective is to determine, in patients with Type 2 diabetes mellitus and stable, documented coronary artery disease, whether 5-year mortality is lower with (1) a strategy of initial coronary revascularization (either PTCA or CABG) combined with intensive medical therapy vs intensive medical therapy alone, and (2) glycemic control achieved by an insulin sensitizaton regimen vs an insulin provision regimen (both to a target HbA1c level of <7.0%). UAB is one of about 50 clinical centers participating in this trial, of about 2,400 patients with follow-up of 5-7 years. The study is presently in its recruitment phase, and no results or publications have yet been forthcoming.